Seeking Alpha

Justin M. Hall's  Instablog

Justin M. Hall
Send Message
In transition, I plan to update my Bio in the near future. -- Justin
  • 8 STRONG BUYS => Rx Investors.com 41 comments
    Jul 8, 2010 10:12 PM | about stocks: INFI, SPPI, CRIS, GHDX, SNTS, VNDA, CYPB, OXGN


     8 STRONG BUYS

     Rx Investors

     7/8/10 10:11 PM ET



    (1) Oxigene - OXGN

    Trading near cash.  This is the CTIC of 2010-2011, but with better science - VDA's novel mechanism of action.  This is a no-brainer while trading at or  near $0.30.  Potential acquisition target at these levels.

    UPDATES

    -- 7/15/10: OxiGene: Dirt Cheap, Lots of Potential

    -- 7/20/10: A Doc's Take on OxiGene's Ophthalmology Program




    SOLD!  (2) Cypress Biosciences - CYPB

    Trading at or below cash; sales from Fibromyalgia drug growing albeit somewhat slowly.

    UPDATES

    -- 7/22/10: I issued a formal sell recommendation for January 2011 $2.50 calls - gain of +140%.

    -- 8/2/10: RXI member and friend, David Kieve, reported a +200% gain on the January 2011 $2.50 calls.

    -- 11/2010: In late November 2010, a formal sell recommedation was [finally] issued for CYPB's common shares.





    SOLD! (3) Vanda Pharmaceuticals - VNDA

    Trading at or below cash; recently approved drug for CNS disorder (schizophrenia, as I recall).

    UPDATE
    Shares of VNDA hit my $10 target on 12/21/10.  While shares are likely to head higher from here, the position has been Closed at Rx Investors.





    (4) Santarus - SNTS

    Trading at 4X earnings with pending catalysts in 2010.





    SOLD! (5) Genomic Health - GHDX

    Diagnostics maker with excellent revenue stream, potential acquisition target

    UPDATE

    -- 12/2010: In early December 2010, GHDX hit my $20 price target.  After an Open Position hits its target, it's Closed.





    SOLD! (6) Curis - CRIS

    Strong pipeline + the support of Roche-Genentech - RHHBY.

    UPDATE

    --8/2010: A formal sell recommendation was issued on shares of CRIS at $1.77 for a nominal gain in August 2010.




    (7) Infinity Pharmaceuticals - INFI

    Strong pipeline, plenty of cash and a revenue stream coming in from collab's.





    (8) Spectrum Pharmaceuticals - SPPI

    - Zevalin sales continue to grow Q/Q. 

    - Evidence demand is increasing with new German Zevalin supplier, now drug available 6 days rather than 2 days each week.

    - 2011: Fusilev FDA decision scheduled for 4/29/11.
      
    - 2012: Eoquin and Belinostat - the latter two have HUGE potential for bladder cancer and PTCL respectively.
     
    -SPPI remains an acquisition target.








    Disclosure: Long SPPI.

Back To Justin M. Hall's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (41)
Track new comments
  • kampaa
    , contributor
    Comments (59) | Send Message
     
    $VNDA A buyout would save the short selling hedge fund from a squeeze spike: story at SocialPicks brokerz.com/_lHzq/

     

    Picked up by Brokerz M&A news; Financial news about mergers and acquisitions (M&A), takeovers and buyouts twitter.com/brokerz_me...

     

    Learn more about $VNDA potential at
    twitter.com/kampaakamp...
    9 Jul 2010, 06:03 AM Reply Like
  • kampaa
    , contributor
    Comments (59) | Send Message
     
    Justin you recommended $OXGN 17 th May and since then the price has dropped 71% from your call at $0.97. stk.ly/9eGyVD

     

    The problem with OXGN is NO money and the private placement and D Warrants (make WHOLE Guarantee).

     

    Some examples (on the # of shares to be issued) from the prospectus are: (1)at an average price of 25 cents 23,421,055 shares would be issued at a conversion price of .001 per share (2)at an average price of 15 cents 43,421,055 shares (3)at an average price of 40 cents only 12,171,055 shares would have to be issued.

     

    Impossible to go through this lid of stocks without any BREAKING news and that can take time if ever they can reach to a deal. IMO the lid is still on. stk.ly/9eGyVD

     

    See sec docs

     

    investor.oxigene.com/s...

     

    investor.oxigene.com/s...
    9 Jul 2010, 06:54 AM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » Hi Kampaa,

     

    What can I say about OXGN and EPCT? Bad calls, tough market. There are risks associated with investing in this environment.

     

    Regarding OXGN, you may be right. While trading at $0.30, it's hard for me to believe that shares will never recover.

     

    Back in early 2009, CTIC experienced the same challenges while trading under the $50 and $35 million NASDAQ global and capital markets listing requirements. To obtain enough cash necessary for its survival, CTIC also issued a ton of shares. At this point in the game, OXGN is nowhere close to CTIC. Plus, it does have some cash - approximately $0.22 / share.

     

    More importantly, here, OXGN's VDA drugs feature a novel mechanism of action, which appears to have some merit and therefore value.

     

    I've seen this scenario play out many times in the past. In these scenarios, shares are pushed to the brink. During this time investors rightfully fear delisting (which has little to no effect on the underlying stock). The uncertainty of bankruptcy looms. Make no mistake, both of these risks are certainly not out of the realm of possibility with OXGN.

     

    That said, I think the positives outweigh the negatives.

     

    (1) OXGN is clearly oversold. (2) Their pipeline of VDAs has some value. And for the second reason alone, I believe shares will recover.

     

    I think we will see the OXGN recovery begin in July or August 2010.

     

    I certainly could be wrong. While shares are trading at or under $0.30, I'm willing to bet otherwise.

     

    -- Nice call on VNDA! I enjoyed reading your twitter entries. Please keep in touch!

     

    Justin
    rxinvestors.com/
    9 Jul 2010, 08:02 AM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » It is worth noting that PFE acquired ENCY in 2008.

     

    Like OXGN and CTIC in 2009, ENCY had little to no cash and was on the brink of delisting. There, PFE acquired ENCY at the last minute for less than $100 million as I recall. ENCY had no prior collab agreement with PFE. Prior to the ENCY acquisition and during the same year, PFE also acquired COLY, another beaten up drug maker similarly situated with OXGN today.

     

    So, I would not be to quick to dismiss the possibility of an OXGN acquisition.

     

    From my view, it's worth a bet when shares are trading at or below $0.30 per share.

     

    Justin
    9 Jul 2010, 08:21 AM Reply Like
  • antisense
    , contributor
    Comments (42) | Send Message
     
    Keep pumping stocks like SPPI and others to no effect. Sorry your picks are as bad as your predictions and you seem to think you are a biotech analyst? Do some more research the bio-tech universe is big find real winners not losers like OXGN and SPPI.
    9 Jul 2010, 09:05 AM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » Antisense, thank you for the feedback. Try to keep in mind, this is just a blog.

     

    I do not think that I am a biotech analyst.
    9 Jul 2010, 10:19 AM Reply Like
  • vvinayak
    , contributor
    Comments (38) | Send Message
     
    Good information Justin, SPPI and SCLN ahvd fallen through roof in last 3 weeks. Can you please put some light on that. Invenstors are looking for some insider information.
    9 Jul 2010, 11:08 AM Reply Like
  • tctwin
    , contributor
    Comments (7) | Send Message
     
    Mr. Hall,
    Why do you only take payment thru PayPal ? A lot of people
    do not care to deal with them.... I understand the negatives of
    paperwork etc. but you might get more subscriptions if you
    allowed a alternative !!
    Thanks
    9 Jul 2010, 01:04 PM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » VV:

     

    As evidenced by the charts above, many stocks have taken a beating.

     

    The issue right now is Risk Aversion.

     

    Continue to add to your existing positions in order to bring your cost basis down (dollar cost averaging). When shares begin to advance again, your positions will become profitable sooner.

     

    I continue to like SCLN. I own various positions in SPPI and will remain invested in the company for the long-term (2011-2012). I do not believe it will stay at these levels forever - close, but not forever. :-) It's enough to drive a sane man into madness.

     

    I hope this helps my friend.

     

    Justin
    9 Jul 2010, 02:05 PM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » TCTwin:

     

    It is good to hear from another mid-westerner!

     

    I will look into other payment alternatives this weekend. Once I have an alternative solution, I will post an update on the site and on this blog.

     

    Thank you for the heads up. I do appreciate it.

     

    Justin
    9 Jul 2010, 02:11 PM Reply Like
  • Bio Burt
    , contributor
    Comments (324) | Send Message
     
    He's right, OXGN will be this year's ctic, and will also go to 0.

     

    This guy has been pumping sppi forever. it does not seem to be working.
    9 Jul 2010, 05:07 PM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » Thank you for your feedback Bio Burt.
    9 Jul 2010, 11:21 PM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » To be fair, I did call SPPI correctly, in part, last summer. Zevalin was approved. Shares exceeded $7.81. My longer-term target will take some time, but I believe it will get there. I'm an investor and build long positions over time. I have made an effort to ensure that this was clear since I began writing here.

     

    In fairness, I have made many other calls in addition to SPPI which make up my complete track record. My other calls include: ARIA, DCTH, INFI, QCOR, RGDX, among several others.

     

    In May, my calls on OXGN and EPCT were terrible. What more can I say? Obviously, I do not share your view that OXGN will go to $0. Quite honestly, that's highly unlikely.

     

    To the best of my knowledge, CTIC did not make it to $0 in 2009. In late January 2009, I picked up shares of CTIC at $0.07. Subsequently, shares hit $0.05 in January and February 2009. During March to early June 2009, shares of CTIC hit above $2.00 and sold off into ASCO. I exited my CTIC positions in April and May 2009 prior to ASCO. Nevertheless, a gain is a gain.

     

    If I'm a SPPI 'pumper' as you suggest, then I am the first to admit that I am doing a terrible job.
    9 Jul 2010, 11:53 PM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » -
    -
    (1) Feel free to review my other articles here:
    seekingalpha.com/autho...

     

    (2) Here are the results I have obtained - my public track record - during 2009 to 2010.
    www.rxinvestors.com/ca...
    10 Jul 2010, 12:06 AM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » -
    -
    (3) On March 21, 2010, my coverage of Spectrum Pharmaceuticals (SPPI) was cited in the Orange County (California) Business Journal.
    www.rxinvestors.com/ar...
    10 Jul 2010, 12:30 AM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » -
    -
    (4) Add SmartHeat (HEAT) to the list of my other calls

     

    (5) On June 25, 2010, I also posted on this blog the results of five short-term trades that I recommended in May and June 2010 at Rx Investors.com
    seekingalpha.com/insta...
    10 Jul 2010, 12:32 AM Reply Like
  • jo103
    , contributor
    Comments (10) | Send Message
     
    Entered Lcypb in the average gate of 2.16$ after the deal with byolain.... Pleasant inker to recognize. The writing became by means of translation on the internet thank you

     

    yosef2006@013.net
    10 Jul 2010, 09:36 AM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » Yosef:

     

    I think I understand the point you are trying to make. You're welcome.

     

    Try to remain patient with your investment as it may take some time.

     

    Nevertheless, I do believe you made a good bet with CYPB at $2.16. Good luck with your investment.

     

    I hope all is well in Hadera. I am a fan and supporter of Israel.

     

    Justin
    10 Jul 2010, 11:13 PM Reply Like
  • jo103
    , contributor
    Comments (10) | Send Message
     
    Biolinerx rose B3 the last days 8% after recovered from the deal of Hmishor. Today she rose B5% with big cycle. It is about time that also my investor cypb they will understand the deal that is good this. Why the investors Busa don't understand the potential B1020
    11 Jul 2010, 10:06 AM Reply Like
  • jo103
    , contributor
    Comments (10) | Send Message
     
    Exploits the momentum : In their Julies from hurry process of her issue in Nasdaq for bizportal well known that/because in the last week of general manager of the company DR. Kinneret Soitski lingered in United States and meets with underwriters permute Kornpld22:01 | 11.07.10 added warning of the past to connect printing rss! Add Lfacebook added Ltwitter updates are warmish and warnings joined us in Facebook followed after us in the tweeter always up to date also in the cellular all the data in real time the company of development of the medicines in their Julies ( 354 | 5.36% ) from hurry process of the issue of the company in Nasdaq, so well known for bizportal. In the last week of general manager of the company DR. Kinneret Soitski lingered in United States and according to the sets meet with potential underwriters that will lead the issue. In the company in their Julies want to exploit the business positive momentum in which situated the company, this after only before three weeks signed the company on deal Lmshor the medicine to the schizophrenia that developed the company ( bl1020 ) with the company Siprs the American. Agreement has a potential of earnings of 365 million dollar. In spite of the positive agreement and the preliminary payment in the extent of 30 million dollar the same she is supposed to receive, in the capital market did not receive the deal positively, among other things on background of the sharp parachuting in the price shares of Siprs. Shares of the American company dropped in/by almost 50% from moment of the declaration on the deal to the value of about 82.1 million dollar. In a similar vein, shares of in their Julies intersect in about 20%, but it is important to point out that/because not yet publication of the deal of the capacity the her Menis to climb the similar rate/lesson. Publication at least for the time being, considerable that/because Bbiolin not really need the cashes, and this inasmuch as that in the end of the first quarter were in the fund of the company about 95 million shekel, amount that not includes in him/it payment of the preliminary grant him likely to receive the company Msiprs. Already before half year, in the end 2009, tested in the company Hbiomd the issue of the company in Nasdaq. Then stood its value of in their Julies on 140 million dollar and according to the reports in the communication of the company examined enlistment according to value more high. At this time, its value of in their Julies stand on 113 million dollar only, almost 30 million this inferior dollar in spite of the progress are business the company. According to the sets, in the company believe at this time that the attractive pricing of the company in United States will help promote the issue rapidly.
    11 Jul 2010, 03:27 PM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » I apologize, but I am having some trouble understanding your comment accurately.

     

    I will try to find more information on the deal that you are referring.
    11 Jul 2010, 11:40 PM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » Yosef:

     

    I will also take a closer look at the drug you mentioned. Make no mistake, I think CYPB is a very good buy at these levels. Give me some time, but I will look even closer at the company.

     

    Justin
    ______________________...

     

    ALL:

     

    Right now, I am preparing an article on OXGN. The article will be posted at Rx Investors.com (link below) in the coming days.

     

    While shares are trading at mere $0.30, OXGN is a bargain. This is a must own right here, right now.

     

    If you hear me now, I am confident that you will thank me later.

     

    Justin
    rxinvestors.com//
    11 Jul 2010, 11:48 PM Reply Like
  • jo103
    , contributor
    Comments (10) | Send Message
     
    In their Julies lurked Aks ltd. ( " the company " ) 12.7.2010 re : Progress in the process to the issue in Nasdaq the company informs in this that/because on day 11.7.2010 decided a directorate of the company to progress in the process to her shares issues of the company and their registering to the commerce by the stock exchange of the Nasdaq that in United States and in this respect to summon an assembly by and large for approval of number of subordinate actions to registering as mentioned. Invitation to the aforesaid served assembly in tandem to this report. Will be marked that/because the company began this already to prepare/take place/ to the process of the issue and in this frame submitted to the authority of securities Hamrikanit from supports of registering in the way is not public when the company of observer that/because document of the next registering will be served in the public way. (Confidential filings ) will be elucidated that/because timing of the issue, her extent and her structure not yet were determined in the final way. More will be elucidated that/because this report does not constitute an offer of sold, offer to the public to acquire or coaxing to the acquisition of securities. Intention of of the company to offer Mniotia to the public in United States as mentioned is information of observer of face of future as his definition in the law of securities, Htshc"h 1968 the based on the present expectations of the company. His materialization is likely or at all of the information is influenced from factors which it's impossible Lharicm in advance and they are not found controled by the company, to the multifactor the risk that characterize activity of the company and situation of market of the securities in United States. Sincerely, in their Julies lurked Aks ltd.

     

    This announcement to the stock exchange from today. They execute an union of shares 10 for 1. I am a holder since yesterday certain amount by the options of the company. My question is. If allowable to issue Bnsd"k when to the obligated ' there are options...
    12 Jul 2010, 02:31 AM Reply Like
  • kyelion
    , contributor
    Comments (17) | Send Message
     
    SPPI - any comment on the unexpected exit of two top managers, (Sandler and Sing) ?
    Furthermore me and other Italian shareholders have often tried invain to get some clarifications from IR : no feedback at all.
    Have you ever had the same problem ?
    thank you
    12 Jul 2010, 03:03 AM Reply Like
  • jo103
    , contributor
    Comments (10) | Send Message
     
    Israel's BioLineRx readies Nasdaq share offer

     

    Digg This Tweet ThisShare on LinkedIn Share on FacebookStocks
    BioLineRX Ltd.
    BLRX.TA
    359.00₪
    +18.00+5.36%9:20am UTC+0300
    TEL AVIV | Mon Jul 12, 2010 2:47am EDT

     

    TEL AVIV July 12 (Reuters) - Israeli drug development company BioLineRx (BLRX.TA) is planning a share offering on U.S. exchange Nasdaq, the company said on Monday.

     

    BioLineRx said its board has decided to advance the process and has called a shareholders' meeting to approve certain measures that must be taken.

     

    The company has already started preparations for an offering and submitted confidential filings to the U.S. Securities and Exchange Commission, BioLineRx said in a statement to the Tel Aviv Stock Exchange.

     

    The next filing is expected to be public, it added.

     

    "It should be clear that the timing, size and structure of the offering have not been finalised," the statement said.

     

    BioLineRx signed a $365 million out-licensing deal last month with Cypress Bioscience (CYPB.O) for its anti-psychotic drug BL-1020. [ID:nLDE65J03G]

     

    Last year New Jersey-based Ikaria Holdings Inc agreed to pay $285 million for a license to develop and market BioLineRx's BL-1040 drug for heart attack patients. [ID:nL6111104]

     

    BL-1040 is a myocardial implant for the treatment of acute myocardial infarction.

     

    (Reporting by Tova Cohen; Editing by Michael Shields)
    12 Jul 2010, 03:45 AM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » Kyelion:

     

    First, it's good to hear from you again! I hope all is well with my investor friends in Italy.

     

    -- No, I have not tried to contact IR recently. That's very odd. Hmmm.

     

    -- Yes, I was surprised about the recent departure of those execs.

     

    I also thought it was interesting that both the CEO and a director(s) also purchased shares again a week or two ago.

     

    In all honesty, I'm not real sure what to make of all these recent developments. They are out of character for this particular company. This is NOT at all the norm at SPPI.

     

    That said, I am NOT convinced that I should view them as a bad sign. In fact, these things may very well be a good sign. As far as I know, the company could be preparing to be acquired.

     

    When I have more information, I will post it for everyone at Rx Investors.com.

     

    Bookmark this URL:
    www.rxinvestors.com/

     

    In the coming days, I will be providing "Regular" content (articles and updates) that everyone will be able to access. So, stay tuned!

     

    Justin
    12 Jul 2010, 09:59 AM Reply Like
  • RTN
    , contributor
    Comments (66) | Send Message
     
    Justin, semi off topic, but could you have a look at INSM for me and maybe comment if you see drawbacks?

     

    Core mangement left, chairman of board acting ceo for over a year.
    125 cash, about 96 cent per share,(130mln float ) no debt, cash flow neutral. One failed trial in 2009, good deal with merck in 2009 as well that got them their cash. Still trial in retinopathy and potential in ALS for their lead product which is a natural occuring key compound in the human body igf1bp3.

     

    Short interest dropped 64% to a mere 1.5mln , covered with forced RUSSEL index fund sales end of june

     

    I wondered if you saw any drawback or not on their balance sheet.
    13 Jul 2010, 04:11 AM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » RTN:

     

    Without looking at their pipeline, you make a good case for the company, INSM.

     

    After quickly reviewing the chart, I think shares are likely to pick up this month or next during more favorable seasonality.

     

    Shares appear to have bottomed in the $0.60's. Expect a pullback in the coming week or two. As shares begin to recover in the back half of this year, I would look to exit at or near $1.00.

     

    I hope this helps! Have a good weekend my friend!

     

    Justin
    Bookmark my site: rxinvestors.com/
    16 Jul 2010, 11:59 PM Reply Like
  • jo103
    , contributor
    Comments (10) | Send Message
     
    Which big cycle there is momentarily this Bcypb. If is done a collection upwards and later collection from down.
    12 Jul 2010, 12:13 PM Reply Like
  • jo103
    , contributor
    Comments (10) | Send Message
     
    If rite 2 tell that/because Bcypb created support B2.16. I think that/because there is collect in share already several days. cycle today high 1.4 million shares & he's continuation of rise in cycles in last period.
    12 Jul 2010, 04:25 PM Reply Like
  • jo103
    , contributor
    Comments (10) | Send Message
     
    If the break in arrives. Cycle about half from the average and this after C70 minutes.
    13 Jul 2010, 10:18 AM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » Yosef:

     

    It was a very good day for CYPB shareholders, +9% on a terrible day for the broader market! Tough market conditions right now, but today's performance by CYPB may be a good sign - indicating shares will continue to advance.

     

    In my view, CYPB is both oversold and way undervalued while shares are trading at a market value below $100 million.

     

    I anticipate that CYPB along with some other names could make significant moves in the back half of the year.

     

    Justin
    ______________________...

     

    ALL:

     

    Broader Market: Investors should see stocks begin to rise again in the coming weeks. A rally is overdue. Look for second correction in October followed by a year-end rally. In the US, the key catalyst will likely be the November 2010 elections. If fiscal conservatives dominate, then the market should rally. If not, then 'Welcome to the Terrordome 2010'. If those left of center do well during the elections, then investors should expect the market to fall and the odds for a 'double dip' will increase dramatically.

     

    As for the small cap drug makers, many of them have been beat up pretty badly during this correction (May 6 to present). Favorable names like those mentioned above are both oversold and undervalued. As result, we might begin to see consolidation pick up in this space. I am hopeful.

     

    Look for AZN to make a big purchase in the coming months, i.e. AGN, BIIB, or GENZ.

     

    While trading under $25 million, I view OXGN as a potential buyout. SPPI remains on the table. Just a hunch, but TEVA could have an interest in SPPI. Please keep in mind, all of this is purely speculation on my part.

     

    Bookmark my site: RxInvestors.com

     

    Over the coming weeks and months, I'm going to shift away from posting entries on this blog. I would prefer to work from one outlet. At Rx Investors, I will post Regular updates for readers here. In addition, I will also be able to take your questions.

     

    Make no mistake, my aim is to earn your business eventually. So, if you make money on my recommendations, then please support my efforts at Rx Investors by subscribing to the site. I am confident that if you allow me the opportunity to earn your business, I will retain it.

     

    ==&gt; Have a good weekend all! <==

     

    Justin
    16 Jul 2010, 11:52 PM Reply Like
  • vvinayak
    , contributor
    Comments (38) | Send Message
     
    Good information regarding CYPB, can any of you tell me the future of CYPB. Stock is beeten down if its up one day and then lost all the glitter on next day. What is your price target and what to aspect from the pipeline
    19 Jul 2010, 12:59 AM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » VV: That's why I set up the site.
    19 Jul 2010, 12:00 PM Reply Like
  • vvinayak
    , contributor
    Comments (38) | Send Message
     
    Mr. Hall you are right. i am recently laid off and my living condition is hand to mouth. i have very little in stock market. in my good days i have sow into into. As soon as i get my job i will be your customer.

     

    thanks any ways. you have very bleassed business
    19 Jul 2010, 02:27 PM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » VV:

     

    Check your gmail account.

     

    Justin
    19 Jul 2010, 03:34 PM Reply Like
  • tctwin
    , contributor
    Comments (7) | Send Message
     
    Great weekend for our Twins !!!!
    Any update on alternative ways to buy your Rx site
    other then PayPal ?
    Also,I have not seen any input on ARIA or Delcath.Your opinion ......

     

    I also read a article that stated SPPI was having problems receiving
    critical manufacuring material because of the problem with the
    volcano activity last quarter in Iceland.Could possible mean sales
    will be down in 2nd Qtr. Any Comment ?
    19 Jul 2010, 02:49 PM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » TCTwin:

     

    Q2 may be a tough one for SPPI. I believe that has been factored into the current share price. The problem does appear to be fixed now.

     

    With 50 paying subscribers at Paypal, I am unable to offer another payment processor. I thought I might be able to offer another alternative, but I cannot For that, I apologize. I hope that does not deter you from subscribing in the future. Paypal is very safe.

     

    Justin
    19 Jul 2010, 03:40 PM Reply Like
  • Justin M. Hall
    , contributor
    Comments (753) | Send Message
     
    Author’s reply » TCTwin:
    I have provided recommendation on ARIA and DCTH at Rx Investors.

     

    As I am trying to build a business, I don't give too much away for free anymore as this would be unfair to existing subscribers.

     

    Justin
    19 Jul 2010, 03:42 PM Reply Like
  • vvinayak
    , contributor
    Comments (38) | Send Message
     
    Mr. Hall thanks your heart is very big. I believe every thing has right time and i humble request you to please read " It's your time". The person who understand the pain of others will like this book

     

    thanks brother

     

    appreciate much
    19 Jul 2010, 08:13 PM Reply Like
  • vvinayak
    , contributor
    Comments (38) | Send Message
     
    i have checked lately that CEO of SPPI is an indian, and their are lot of insider activity happen in last 3 months. Seems like this company will come up with big surprises, when that is what you need to find out.

     

    good luck to all who owns SPPI
    19 Jul 2010, 08:41 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.